ArticleScientific reports2025
Zinc alleviates vascular calcification by activating ERK1/2-mediated autophagy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Chronic kidney disease (CKD) causes a significant health and economic burden across the world. This study aimed to evaluate the effects of zinc on CKD-mineral bone disorder (CKD-MBD) and autophagy in CKD rats by a diet containing 0.25% adenine and low vitamin K and to explore its mechanism of action on autophagy and calcification in a vascular smooth muscle cell (VSMC) calcification model using 10 mM β-glycerophosphate (β-GP). In vivo experiments showed that zinc supplementation improved blood and urinary biochemistry, corrected abnormalities related to bone metabolism in rats with CKD, promoted autophagy, and reduced aortic calcification. In vitro, zinc reduced the calcification of VSMCs induced by β-GP. During VSMC calcification, zinc further upregulated autophagy levels and the phosphorylated extracellular regulatory kinase1/2 (ERK1/2) levels in a high-phosphorus environment. Pretreatment with 3-methyladenine (3-MA), an autophagy inhibitor, or with U0126, an ERK1/2 pathway inhibitor, decreased autophagy and increased calcification. In conclusion, zinc improved CKD-MBD by inhibiting vascular calcification (VC) and ameliorating bone metabolism disorders. Furthermore, zinc alleviates VC in CKD by activating ERK1/2-mediated autophagy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.